BXTA Celebrates 10 Years of Supporting Improved Prostate Cancer Outcomes

In Summer 2023, BXTA celebrates its 10th anniversary as we reinforce our commitment to helping eradicate cancer.

Founded in 2013 as a specialist provider of low dose-rate (LDR) brachytherapy seeds for prostate cancer treatment, we are extremely proud of the growth and outcomes we have achieved in these last ten years, having become a leading international uro-oncology organisation, committed to providing the most innovative solutions in cancer diagnosis and treatment.

Today, our innovative technology, combined with an unrelenting commitment to service excellence, supports healthcare professionals worldwide to eradicate cancer, extend life and create better quality outcomes for patients.

Working with over 400 hospitals internationally and treating 180,000 patients across UK, Europe and Australasia, at BXTA we are passionate about Prostate Cancer care. Indeed, the 10,000th LDR brachytherapy patient was treated at Royal Surrey County Hospital in Guildford, England, in March 2022.

Since 2018, BXTA has also been supporting the international (#TRexit) drive to eradicate the transrectal (TRUS) biopsy from the prostate cancer pathway, acting as the exclusive distributor for the PrecisionPoint™ Transperineal Access System which enables freehand, transperineal biopsy under local anaesthetic (LATP). We remain fully committed to continuing work in this regard, promoting educational courses, training clinicians and clinical nurse specialists, and raising awareness of the benefits of LATP to hospitals and patients alike.

Our products and service are underpinned by the depth and breadth of our Customer Operations Team, a highly experienced, multilingual team, dedicated to supporting our prostate cancer centre partners with service reliability and excellence.

As we look ahead to the next ten years, we will maintain our ambitious growth plans, both geographically and innovatively, in striving forward with passion to help achieve the best possible cancer outcomes, while remaining committed to the highest levels of support for existing customers.